Skip to main content
U.S. flag

An official website of the United States government

Here’s how you know

Dot gov

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

HTTPS

Secure .gov websites use HTTPS
A lock (LockA locked padlock) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

HHS.gov
  • About HHS
  • Programs & Services
  • Grants & Contracts
  • Laws & Regulations

Breadcrumb

  1. Home
  2. About
  3. News
  4. Statement by HHS Secretary Becerra on FDA Approval of Additional Bavarian Nordic Monkeypox Vaccine
  • News
  • Blog
  • HHS Live
  • Podcasts
  • Media Guidelines for HHS Employees
FOR IMMEDIATE RELEASE
July 27, 2022
Contact: HHS Press Office
202-690-6343
media@hhs.gov

Statement by HHS Secretary Becerra on FDA Approval of Additional Bavarian Nordic Monkeypox Vaccine

Today, the Food and Drug Administration (FDA) announced it has approved a supplement to the biologics license for the JYNNEOS Vaccine, which is manufactured by Bavarian Nordic and approved to prevent smallpox and monkeypox. 

U.S. Department of Health and Human Services Secretary Xavier Becerra issued the following statement:

“This action by the FDA is a critical step forward in our plans to strengthen and accelerate our monkeypox response, which includes distributing a safe and effective vaccine to those at highest risk of exposure to monkeypox.  The expedited inspection and approval by FDA of Bavarian Nordic’s fill-and-finish capabilities means that an additional 786,000 doses of vaccine are now available for use in the U.S.  HHS is working to make these doses available to states and jurisdictions as soon as possible to fulfill their needs and will announce allocations tomorrow. 

“Aggressively responding to the monkeypox outbreak is a critical priority for HHS. Within days of the first U.S. case, we activated a multi-pronged response, significantly increasing vaccine supply and distribution, expanding access to tests, making treatments available for free, and educating the public on steps to reduce risk of infection.  We will continue to accelerate and strengthen our response in the coming days, and will work with partners on the ground, in the community, and internationally to combat this virus and protect those at risk.  I applaud the entire FDA team for their tireless work in making this additional vaccine available as quickly as possible while ensuring it meets the highest standards of quality and safety.”

###
Note: All HHS press releases, fact sheets and other news materials are available at https://www.hhs.gov/news.
Like HHS on Facebook, follow HHS on Twitter @HHSgov, and sign up for HHS Email Updates.
Last revised: July 27, 2022

Sign Up for Email Updates

Receive the latest updates from the Secretary, Blogs, and News Releases

Sign Up

Subscribe to RSS

Receive latest updates

Subscribe to our RSS

Related News Releases

  • HHS Deploys Public Health Service Officers to Hawaii

  • HHS Secretary Xavier Becerra Declares Public Health Emergency for Georgia

  • HHS Announces Details of Partnership with Regeneron to Develop Life-Saving Monoclonal Antibodies

Related Blog Posts

  • HHS Blog thumbnail

    Climate-Related Hazards and the Importance of Resiliency

Media Inquiries

For general media inquiries, please contact media@hhs.gov.

Content created by Assistant Secretary for Public Affairs (ASPA)
Content last reviewed July 27, 2022
Back to top
  • Contact HHS
  • Careers
  • HHS FAQs
  • Nondiscrimination Notice
  • HHS Archive
  • Accessibility
  • Privacy Policy
  • Viewers & Players
  • Budget/Performance
  • Inspector General
  • Web Site Disclaimers
  • EEO/No Fear Act
  • FOIA
  • The White House
  • USA.gov
  • Vulnerability Disclosure Policy

Sign Up for Email Updates

Receive the latest updates from the Secretary, Blogs, and News Releases.

Sign Up
HHS Logo

HHS Headquarters

200 Independence Avenue, S.W.
Washington, D.C. 20201
Toll Free Call Center: 1-877-696-6775​